Looking for a reliable tool to identify hypercoagulant markers for cancer risk and prognosis: the HYPERCAN study
The HYPERCAN (HYPERcoagulation in CANcer) study (registered at www.clinicaltrials.gov; NCT02622815) is an ongoing,...
Thrombosis and cancer
Isolated Distal DVT In Cancer Patients: What Do Recent Studies Suggest?
In a recent issue of the Journal of Thrombosis and Hemostasis, we report that cancer patients with isolated distal deep...
Measurement of extracellular vesicles and their role in cancer-associated thrombosis
Extracellular vesicles (EV) are submicron vesicles released from activated cells, apoptotic cells and cancer cells...
Direct oral anticoagulants for the treatment of cancer-associated thrombosis
Cancer-associated venous thromboembolism (VTE) is known to impact up to one-fifth of patients with cancer. The...
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
The American Society of Clinical Oncology just published the new recommendations regarding VTE prophylaxis and...
Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy
Approximately 4% of cancer patients have non-valvular atrial fibrillation (NVAF) and require anticoagulation for...
Cancers as coagulant mosaics
Cancers are potent inducers of abnormal blood clotting, which usually heralds a more aggressive course of the disease...
Arterial Thromboembolism in Occult Cancer
In 1865, Armand Trousseau famously described unexplained thrombotic events as a first manifestation of occult...
Contemporary breast cancer treatment-associated venous thromboembolism
Breast cancer patients have a three-to four fold increased risk of venous thromboembolism (VTE) when compared to women...
Mouse models of cancer-associated thrombosis
Cancer patients have 4-7 fold increased risk of venous thromboembolism (VTE) compared with a general population ....